New combo therapy targets advanced cancers in early trial
NCT ID NCT07508761
First seen Apr 09, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tests a new drug (IPG7236) combined with an immunotherapy (toripalimab) in adults with advanced solid tumors that have spread or cannot be removed. The goal is to check safety, how the body processes the drugs, and whether they shrink tumors. About 52 people will join this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Gaobo Tumor Hospital
Shanghai, PuDongXinQu, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.